Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eimc.2017.04.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The dalbavancin dilemma: Establishment of a new formulary restriction workflow to balance access and stewardship.
Am J Health Syst Pharm
December 2024
Department of Pharmacy Services, Mayo Clinic, Rochester, MN, USA.
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFMolecular insights into Dalbavancin's blockade of ACE2-spike protein interaction in SARS-CoV-2.
Phys Chem Chem Phys
December 2024
School of Physics and Electronics, Shandong Normal University, Jinan, 250014, China.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic and a serious impact on human life and health. The spread of this virus, coupled with the emergence of many mutants, has posed increasingly formidable challenges to the design and development of antiviral drugs. Recently, it has been discovered that dalbavancin can bind to angiotensin-converting enzyme 2 (ACE2) of host cells with high affinity, blocking the interaction between the spike protein and ACE2, thereby making it a potentially promising anti-SARS-CoV-2 drug.
View Article and Find Full Text PDFModel-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections.
Antibiotics (Basel)
November 2024
Hospital Pharmacy, Heidelberg University Hospital, Im Neuenheimer Feld 670, 69120 Heidelberg, Germany.
Increasing evidence suggests that dalbavancin is an effective long-term treatment for ventricular assist device (VAD) infections, with various prolonged dosing regimens currently in use. This retrospective study aimed to assess dalbavancin pharmacokinetics in VAD patients and identify optimal, feasible dosing regimens for long-term suppressive outpatient therapy. Data from Heidelberg University Hospital's VAD register were analyzed using non-linear mixed-effects modeling for pharmacokinetic analysis and dosing simulations (Lixoft).
View Article and Find Full Text PDFSafety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections.
Antibiotics (Basel)
November 2024
Department of Statistical Sciences, University of Bologna, 40126 Bologna, Italy.
Dalbavancin is a long-acting lipoglycopeptide, approved for treatment of skin and skin structure infections. Its PK/PD profile and safety allow for short hospital stays even in the case of difficult-to-treat infections requiring long courses of therapy, e.g.
View Article and Find Full Text PDFA Challenging Case of Isolated Pulmonic Valve Endocarditis With Septic Embolic and High-Grade Bacteremia.
Cureus
October 2024
Department of Medicine, MetroWest Medical Center, Framingham, USA.
Article Synopsis
- A challenging case involved a 31-year-old female intravenous drug user who presented with severe symptoms, including fever and shortness of breath, and was diagnosed with high-grade MSSA bacteremia and multiple pulmonary emboli.
- Despite having significant heart complications like a large vegetation on the pulmonic valve, the patient was treated without valve replacement and was closely monitored with follow-up care and additional medications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!